Dublin, Ireland (PressExposure) June 23, 2014 -- Martin Hallbeck from Linkoping University will speak on "A Cell Model for Phenotypic Drug Screening for Alzheimer's Disease" at the Cell Based Assay & Screening Technologies Conference, to be held October 7-8, 2014 in Dublin, Ireland.
Dr. Hallbeck, who is currently an associate professor of pathology, will discuss the potential of human neuronal cell models, including induced pluripotent stem cells, to understand the progression of neurodegenerative disorders and the possibility to use these models in phenotypic based drug screening.
Neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease have a large and increasing impact on today's society. There is an emerging understanding of intracellular oligomeric protein aggregates as drivers of these diseases. Synaptic transfer of such aggregates from neuron-to-neuron in a prion-like fashion could, with seeding capabilities, explain the progression of these diseases between anatomically associated regions. However, the cellular mechanisms of this spread are unknown, and it is uncertain whether or not it is possible to interfere with the transfer.
Dr. Hallbeck will describe how his group has developed a neuronal 3D co-culture cell model to study the synaptic transfer of fluorescently labeled neurodegenerative proteins (Nath et al. J. Neurosci 2012). This model is ideal to study the cellular and synaptic mechanisms of transfer, and since there is an urgent need for new treatment approaches for the neurodegenerative disorders, his group has redesigned this model to a format suitable for unbiased phenotypic screening of small molecule libraries.
For more information on Dr. Hallbeck's presentation, as well as the conference, please visit http://www.gtcbio.com/cbast2014.
Cell based assay conference
Screening technologies conference
cellular and synaptic mechanisms of transfer
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.